Clinical Trials · NCT00851773
Safety, Tolerability, and Profile of Action of Drug in the Body of NN9535 in Healthy Male Japanese and Caucasian Subjects
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 84
- Start date
- Feb 2009
- Locations
- 1 site, United Kingdom
- Primary endpoint
- Adverse events